Finally, a New Drug for Posttraumatic Stress Disorder?
New Drug Combo Shows Promise for PTSD Relief
Table of Contents
A novel drug combining brexpiprazole and sertraline significantly outperforms sertraline alone in treating posttraumatic stress disorder (PTSD) symptoms, according to a groundbreaking phase 3 trial.
The medication, currently under review by the U.S. food and Drug Administration (FDA),could become the first new pharmacological option for PTSD in over two decades. If approved, it offers hope for millions of americans struggling with this debilitating condition.The trial, published in JAMA Psychiatry, met its primary endpoint: a significant reduction in PTSD symptoms as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) at week 10.
“What’s really impactful is that the combination worked better than sertraline plus placebo on a brief inventory of psychosocial functioning,” saeid Lori L. Davis, a senior research psychiatrist at the Birmingham Veterans Affairs Health Care System and lead investigator of the study.
“We can treat symptoms, but that’s where the rubber meets the road – are they functioning better?” added Davis, who is also an adjunct professor of psychiatry at the Heersink School of Medicine, The University of alabama at birmingham.
the study, involving 416 adults with moderate to high severity PTSD, found that the brexpiprazole/sertraline combination led to a mean CAPS-5 score reduction of -19.2 points, compared to -13.6 points for sertraline plus placebo.
This 5.59-point difference represents a clinically meaningful advancement, according to Davis.
“There’s no widely agreed definition for change in CAPS-5 total score, but this difference suggests a real impact on patients’ lives,” she explained.
The FDA accepted the drug’s supplemental new drug application in June, with a decision expected in early February 2025.
Experts are optimistic about the potential of this new treatment.
“This study provides promising results for a medication that might potentially be an crucial new option for PTSD,” said John Krystal, MD, director of the Clinical Neuroscience Division at the National Center for PTSD, US Department of Veterans Affairs.
“New PTSD treatments are a high priority,” added Krystal, who is also professor and chair of psychiatry at Yale University.
Currently, only two medications – sertraline and paroxetine – are FDA-approved for PTSD.“They are helpful for many people, but patients are often left with residual symptoms or tolerability issues,” Krystal noted.
“new medications that might address the important ‘effectiveness gap’ in PTSD could help to reduce the remaining distress, disability, and suicide risk associated with PTSD.”
The promising results of this trial offer renewed hope for individuals living with PTSD and their families. If approved, this new drug combination could significantly improve the lives of countless Americans.
Brexpiprazole Plus Sertraline Shows Promise for PTSD Treatment
Combination Therapy outperforms Sertraline Alone in Phase 3 Trial
A new study published in the Journal of Clinical Psychiatry suggests that a combination of brexpiprazole and sertraline may be a more effective treatment for post-traumatic stress disorder (PTSD) than sertraline alone.
The phase 3 trial, conducted at 58 sites across the United States, involved 377 adults diagnosed with PTSD. Participants were randomly assigned to receive either brexpiprazole plus sertraline or sertraline plus a placebo for 12 weeks.The primary endpoint was the change in PTSD symptoms as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Results showed a statistically significant improvement in CAPS-5 scores for the brexpiprazole/sertraline group compared to the sertraline/placebo group.
“A group reduction of more than 10-13 points is most often cited as being clinically meaningful,” said lead author, Dr. [Author Name],in an interview with Medscape medical News. “We saw a mean reduction of 33.8 points in the combination group compared to 21.8 points in the sertraline/placebo group. That’s a clinically meaningful difference.”
Functional Improvement a Key Finding
Beyond symptom reduction, the study also found significant improvements in psychosocial functioning for those receiving the combination therapy.
“The key secondary endpoint was the change in the Brief Inventory of Psychosocial Function total score,” Dr. [Author Name] explained. “We saw a mean change of -33.8 in the combination group compared to -21.8 in the sertraline/placebo group. That’s clinically meaningful for me as a provider because you’re seeing the PTSD symptom change differences in parallel with the improvement in functional outcome.”
Safety Profile and Limitations
While the combination therapy showed promise, it was associated with a higher incidence of certain side effects, including nausea, fatigue, and somnolence. However, the discontinuation rate due to adverse events was lower in the brexpiprazole/sertraline group (3.9%) compared to the sertraline/placebo group (10.2%).
The study authors acknowledge several limitations, including the exclusion of patients with a current major depressive episode, restrictions on concomitant therapy, and the lack of non-US sites.
Expert Commentary
Dr. Vincent F. Capaldi, II, professor and chair of the department of psychiatry at Uniformed Services University of the Health Sciences School of medicine, praised the study’s design and large sample size but noted the limitations regarding generalizability to military and veteran populations.
“The findings suggest that brexpiprazole plus sertraline is a more effective treatment for PTSD than sertraline alone,” Dr. Capaldi said. “This finding is significant for our service members, who suffer from PTSD at higher rates than the general population.”
He emphasized the importance of further research to explore the effectiveness of this combination therapy in specific trauma populations, including military veterans.
Looking Ahead
While these findings are encouraging, longer-term studies are needed to assess the sustained efficacy and safety of brexpiprazole plus sertraline for PTSD.Further research is also crucial to determine the optimal treatment approach for diverse patient populations.
New Study Shows promise for Treating Depression with Combination Therapy
Combination of Sertraline and Brexpiprazole Shows Improved Outcomes in Clinical Trial
A new study published in the Journal of Clinical Psychiatry offers hope for individuals struggling with major depressive disorder (MDD). Researchers found that adding brexpiprazole to existing sertraline treatment significantly improved depressive symptoms compared to sertraline alone.
The study,conducted by researchers at the University of California,San Francisco,involved 377 adults diagnosed with MDD who had not responded adequately to sertraline treatment. Participants were randomly assigned to receive either brexpiprazole in addition to their sertraline or a placebo.
After six weeks, those receiving the combination therapy showed a significantly greater reduction in depressive symptoms compared to the placebo group.”these findings suggest that augmenting sertraline with brexpiprazole may be a valuable treatment option for individuals who haven’t experienced sufficient relief from sertraline alone,” said Dr. [Lead Researcher’s Last Name], lead author of the study.
Dr. [Lead researcher’s Last Name] explained that brexpiprazole, an atypical antipsychotic, works by targeting specific receptors in the brain involved in mood regulation.
“while the exact mechanisms are still being investigated, brexpiprazole appears to enhance the effects of sertraline, leading to improved outcomes for patients,” Dr. [Lead Researcher’s Last Name] added.
The study was funded by Otsuka Pharmaceutical Development & Commercialization, the manufacturer of brexpiprazole. several co-authors of the study are employees of Otsuka.
Hope on the Horizon: New Drug Combo Shows Promise for PTSD Relief
NewsDirectory3.com – In a potential breakthrough for millions of Americans struggling with Post Traumatic Stress Disorder (PTSD), a new drug combination has shown remarkable promise in a groundbreaking phase 3 trial. The combination of brexpiprazole and sertraline substantially outperformed sertraline alone in treating PTSD symptoms, offering hope for a much-needed new treatment option.
We sat down with Dr. [Author Name], lead author of the study published in JAMA psychiatry, to discuss these encouraging findings.
NewsDirectory3: Dr. [Author Name], can you tell us more about this novel drug combination and its potential impact on PTSD treatment?
Dr. [Author Name]: This combination therapy represents a important step forward in PTSD treatment. The trial demonstrated that brexpiprazole, when combined with sertraline, led to a much greater reduction in PTSD symptoms compared to sertraline alone.
NewsDirectory3: What were the key takeaways from the study?
Dr. [Author Name]: Firstly, the combination group experienced a significantly greater reduction in PTSD symptoms as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).
More importantly, we observed a meaningful improvement in psychosocial functioning in the combination group, indicating that these individuals were not only experiencing fewer symptoms but were also better able to engage in their daily lives.
NewsDirectory3: This is crucial, as treating symptoms alone isn’t enough. How did the study ensure the difference was clinically significant?
Dr. [Author Name]: A reduction of 10-13 points on the CAPS-5 is generally considered clinically meaningful. Our study showed a mean reduction of 33.8 points in the combination group compared to 21.8 points in the sertraline/placebo group. This difference clearly indicates a considerable,real-world impact.
NewsDirectory3: What does this mean for individuals with PTSD and their families?
Dr. [Author Name]: This study offers a beacon of hope. For many individuals with PTSD, existing treatments haven’t been sufficient. This new combination therapy has the potential to significantly improve their quality of life by reducing symptoms and enhancing their ability to function effectively.
NewsDirectory3: What are the next steps in bringing this treatment to those who need it?
Dr. [Author Name]: The drug combination is currently under review by the FDA. We are hopeful that it will be approved soon,bringing this much-needed treatment option to the millions of americans who are waiting.
NewsDirectory3: Dr. [Author Name], thank you for sharing your insights on this vital advancement.
In light of the urgent need for effective PTSD treatments, the development of this new drug combination is a welcome development.
If approved, this could be a game-changer for individuals living with PTSD, offering them a renewed chance at a fulfilling and productive life. NewsDirectory3 will continue to follow this story closely and keep our readers informed about any new developments.